LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on gene therapy for muscular dystrophy. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat muscular dystrophy.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Muscular dystrophy: Market overview
A muscular dystrophy is a group of muscle disease that causes an increasing weakening and breakdown of degeneration of skeletal muscles. The individuals suffering from muscular dystrophy start losing muscle mass. The most common cause of muscular dystrophy is the mutation of the protein dystrophin. It is also caused by the genetic mutations that interfere with the muscle protein production. Factors such as the site of affected muscles, the degree of weakness, progression speed, and the first sign of symptoms will decide the type of muscular dystrophy.
According to a senior market research analyst at Technavio, “Dystrophin is a part of complex group of proteins that enable muscles to work correctly. There are over 30 various types of dystrophies with a few being the most common types such as Duchenne muscular dystrophy, Becker muscular dystrophy, and limb-girdle muscular dystrophy. Duchenne muscular dystrophy occurs mostly in boys and very rarely in girls. According to various studies, the average life expectancy of patients with Duchenne muscular dystrophy is around 26 years, while the life expectancy of other types of muscular dystrophies is slightly higher.”
Muscular dystrophy: Segmentation analysis
This pipeline analysis report segments the muscular dystrophy market based on therapies employed (monotherapy), RoA (intravenous and parenteral), therapeutic modality (gene and oligonucleotides), targets (micro-dystrophin, exon 51, exon 53, beta-sarcoglycan, alpha-sarcoglycan, dysferlin, anoctamin 5, gamma-sarcoglycan, and mini-dystrophin), MoA (gene therapy and antisense gene therapy), geographical segmentation (US, UK, and France) and recruitment status (active, not recruiting and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on the mechanism of action, around 88% of the molecules that are being investigated for the treatment of muscular dystrophy are gene therapy.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Type of players
- Company overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.